345 related articles for article (PubMed ID: 10527849)
1. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.
van Beek E; Pieterman E; Cohen L; Löwik C; Papapoulos S
Biochem Biophys Res Commun; 1999 Oct; 264(1):108-11. PubMed ID: 10527849
[TBL] [Abstract][Full Text] [Related]
2. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.
van Beek E; Pieterman E; Cohen L; Löwik C; Papapoulos S
Biochem Biophys Res Commun; 1999 Feb; 255(2):491-4. PubMed ID: 10049736
[TBL] [Abstract][Full Text] [Related]
3. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
4. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.
Räikkönen J; Taskinen M; Dunford JE; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Biophys Res Commun; 2011 Apr; 407(4):663-7. PubMed ID: 21420384
[TBL] [Abstract][Full Text] [Related]
5. Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry.
Jauhiainen M; Mönkkönen H; Räikkönen J; Mönkkönen J; Auriola S
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):2967-75. PubMed ID: 19665949
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
7. Terpenoid biosynthesis and the stereochemistry of enzyme-catalysed allylic addition-elimination reactions.
Cane DE; Abell C; Harrison PH; Hubbard BR; Kane CT; Lattman R; Oliver JS; Weiner SW
Philos Trans R Soc Lond B Biol Sci; 1991 May; 332(1263):123-9. PubMed ID: 1678531
[TBL] [Abstract][Full Text] [Related]
8. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
[TBL] [Abstract][Full Text] [Related]
9. Purification of geranylgeranyl diphosphate synthase from bovine brain.
Sagami H; Morita Y; Korenaga T; Ogura K
Acta Biochim Pol; 1994; 41(3):293-302. PubMed ID: 7856400
[TBL] [Abstract][Full Text] [Related]
10. Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate.
Oizumi T; Yamaguchi K; Funayama H; Kuroishi T; Kawamura H; Sugawara S; Endo Y
Basic Clin Pharmacol Toxicol; 2009 May; 104(5):384-92. PubMed ID: 19413658
[TBL] [Abstract][Full Text] [Related]
11. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
Thompson K; Dunford JE; Ebetino FH; Rogers MJ
Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
[TBL] [Abstract][Full Text] [Related]
12. Farnesyl pyrophosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay.
Glickman JF; Schmid A
Assay Drug Dev Technol; 2007 Apr; 5(2):205-14. PubMed ID: 17477829
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid-induced IPP/ApppI production in vivo.
Mönkkönen H; Ottewell PD; Kuokkanen J; Mönkkönen J; Auriola S; Holen I
Life Sci; 2007 Sep; 81(13):1066-70. PubMed ID: 17850825
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and molecular mechanisms of action of bisphosphonates.
Rogers MJ; Crockett JC; Coxon FP; Mönkkönen J
Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
[TBL] [Abstract][Full Text] [Related]
16. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
Mitrofan LM; Pelkonen J; Mönkkönen J
Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819
[TBL] [Abstract][Full Text] [Related]
17. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
18. Rubber elongation by farnesyl pyrophosphate synthases involves a novel switch in enzyme stereospecificity.
Light DR; Lazarus RA; Dennis MS
J Biol Chem; 1989 Nov; 264(31):18598-607. PubMed ID: 2808389
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway.
Keller RK; Fliesler SJ
Biochem Biophys Res Commun; 1999 Dec; 266(2):560-3. PubMed ID: 10600541
[TBL] [Abstract][Full Text] [Related]
20. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
